azd9291 and rociletinib in t790m-mutant nsclc
Published 9 years ago • 1.3K plays • Length 3:45Download video MP4
Download video MP3
Similar videos
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc
-
8:30
third-generation egfr inhibitors in nsclc
-
6:14
third-generation egfr inhibitors in nsclc
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc
-
5:20
rociletinib/osimertinib for egfr t790m-negative nsclc
-
3:48
azd9291, an egfr-tki, for t790m-mediated resistance in non-small cell lung cancer
-
3:13
osimertinib responses after rociletinib treatment of t790m-positive nsclc
-
0:58
dr. camidge on inhibiting initial activating egfr mutations and the t790m resistance mutation
-
5:45
osimertinib in t790m-mutant lung cancer
-
3:59
osimertinib for egfr t790m resistance mutations in nsclc
-
2:34
goldman: rociletinib in egfr-mutated nsclc
-
11:36
azd9291 for acquired resistance in egfr positive lung cancer
-
4:48
third-generation egfr inhibitors in nsclc
-
5:29
osimertinib for the t790m resistance mutation
-
4:04
treating with osimertinib in egfr-mutated nsclc
-
4:50
tatton: phase 1b trial of azd9291 for egfr-mutant lung cancer
-
2:50
sequencing with osimertinib in egfr-mutated nsclc
-
3:40
next-generation egfr inhibitors in patients with non-t790m resistance
-
2:15
what is t790m?